These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 24418164)

  • 1. Managed ventricular pacing compared with conventional dual-chamber pacing for elective replacement in chronically paced patients: results of the Prefer for Elective Replacement Managed Ventricular Pacing randomized study.
    Botto GL; Ricci RP; Bénézet JM; Nielsen JC; De Roy L; Piot O; Quesada A; Quaglione R; Vaccari D; Garutti C; Vainer L; Kozák M;
    Heart Rhythm; 2014 Jun; 11(6):992-1000. PubMed ID: 24418164
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association between ventricular pacing and persistent atrial fibrillation in patients indicated to elective pacemaker replacement: Results of the Prefer for Elective Replacement MVP (PreFER MVP) randomized study.
    Ricci RP; Botto GL; Bénézet JM; Nielsen JC; De Roy L; Piot O; Quesada A; Quaglione R; Vaccari D; Mangoni L; Grammatico A; Kozák M;
    Heart Rhythm; 2015 Nov; 12(11):2239-46. PubMed ID: 26142300
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multicenter, prospective, randomized safety and efficacy study of a new atrial-based managed ventricular pacing mode (MVP) in dual chamber ICDs.
    Sweeney MO; Ellenbogen KA; Casavant D; Betzold R; Sheldon T; Tang F; Mueller M; Lingle J;
    J Cardiovasc Electrophysiol; 2005 Aug; 16(8):811-7. PubMed ID: 16101620
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized pilot study of a new atrial-based minimal ventricular pacing mode in dual-chamber implantable cardioverter-defibrillators.
    Sweeney MO; Shea JB; Fox V; Adler S; Nelson L; Mullen TJ; Belk P; Casavant D; Sheldon T
    Heart Rhythm; 2004 Jul; 1(2):160-7. PubMed ID: 15851147
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Managed ventricular pacing vs. conventional dual-chamber pacing for elective replacements: the PreFER MVP study: clinical background, rationale, and design.
    Quesada A; Botto G; Erdogan A; Kozak M; Lercher P; Nielsen JC; Piot O; Ricci R; Weiss C; Becker D; Wetzels G; De Roy L;
    Europace; 2008 Mar; 10(3):321-6. PubMed ID: 18308753
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The MINERVA study design and rationale: a controlled randomized trial to assess the clinical benefit of minimizing ventricular pacing in pacemaker patients with atrial tachyarrhythmias.
    Funck RC; Boriani G; Manolis AS; Püererfellner H; Mont L; Tukkie R; Pisapia A; Israel CW; Grovale N; Grammatico A; Padeletti L;
    Am Heart J; 2008 Sep; 156(3):445-51. PubMed ID: 18760124
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New-generation atrial antitachycardia pacing (Reactive ATP) is associated with reduced risk of persistent or permanent atrial fibrillation in patients with bradycardia: Results from the MINERVA randomized multicenter international trial.
    Padeletti L; Pürerfellner H; Mont L; Tukkie R; Manolis AS; Ricci R; Inama G; Serra P; Scheffer MG; Martins V; Warman EN; Vimercati M; Grammatico A; Boriani G;
    Heart Rhythm; 2015 Aug; 12(8):1717-25. PubMed ID: 25869753
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Dual Chamber and VVI Implantable Defibrillator (DAVID) Trial: rationale, design, results, clinical implications and lessons for future trials.
    Wilkoff BL;
    Card Electrophysiol Rev; 2003 Dec; 7(4):468-72. PubMed ID: 15071277
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atrial antitachycardia pacing and managed ventricular pacing in bradycardia patients with paroxysmal or persistent atrial tachyarrhythmias: the MINERVA randomized multicentre international trial.
    Boriani G; Tukkie R; Manolis AS; Mont L; Pürerfellner H; Santini M; Inama G; Serra P; de Sousa J; Botto GL; Mangoni L; Grammatico A; Padeletti L;
    Eur Heart J; 2014 Sep; 35(35):2352-62. PubMed ID: 24771721
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Managed Ventricular pacing versus VVI 40 Pacing (MVP) Trial: clinical background, rationale, design, and implementation.
    Sweeney MO; Ellenbogen KA; Miller EH; Sherfesee L; Sheldon T; Whellan D
    J Cardiovasc Electrophysiol; 2006 Dec; 17(12):1295-8. PubMed ID: 17081208
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reducing unnecessary right ventricular pacing with the managed ventricular pacing mode in patients with sinus node disease and AV block.
    Gillis AM; Pürerfellner H; Israel CW; Sunthorn H; Kacet S; Anelli-Monti M; Tang F; Young M; Boriani G;
    Pacing Clin Electrophysiol; 2006 Jul; 29(7):697-705. PubMed ID: 16884504
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduction of unnecessary right ventricular pacing by managed ventricular pacing and search AV+ algorithms in pacemaker patients: 12-month follow-up results of a randomized study.
    Chen S; Chen K; Tao Q; Zheng L; Shen F; Wu S; Fan J; Xu G; Wang L; Zhou X; Zhang S;
    Europace; 2014 Nov; 16(11):1595-602. PubMed ID: 24706091
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term clinical effects of ventricular pacing reduction with a changeover mode to minimize ventricular pacing in a general pacemaker population.
    Stockburger M; Boveda S; Moreno J; Da Costa A; Hatala R; Brachmann J; Butter C; Garcia Seara J; Rolando M; Defaye P
    Eur Heart J; 2015 Jan; 36(3):151-7. PubMed ID: 25179761
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of PR interval and pacing mode on persistent atrial fibrillation incidence in dual chamber pacemaker patients: a sub-study of the international randomized MINERVA trial.
    Boriani G; Pieragnoli P; Botto GL; Puererfellner H; Mont L; Ziacchi M; Manolis AS; Gulizia M; Tukkie R; Landolina M; Ricciardi G; Cicconelli M; Grammatico A; Biffi M
    Europace; 2019 Apr; 21(4):636-644. PubMed ID: 30649270
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The PhysioVP-AF study, a randomized controlled trial to assess the clinical benefit of physiological ventricular pacing vs. managed ventricular pacing for persistent atrial fibrillation prevention in patients with prolonged atrioventricular conduction: design and rationale.
    Pastore G; Bertini M; Bonanno C; Coluccia G; Dell'Era G; De Mattia L; Grieco D; Katsouras G; Maines M; Marcantoni L; Marinaccio L; Paglino G; Palmisano P; Ziacchi M; Zoppo F; Noventa F
    Europace; 2023 May; 25(5):. PubMed ID: 36974970
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual-chamber pacing or ventricular backup pacing in patients with an implantable defibrillator: the Dual Chamber and VVI Implantable Defibrillator (DAVID) Trial.
    Wilkoff BL; Cook JR; Epstein AE; Greene HL; Hallstrom AP; Hsia H; Kutalek SP; Sharma A;
    JAMA; 2002 Dec; 288(24):3115-23. PubMed ID: 12495391
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The value of DDD pacing in patients with an implantable cardioverter defibrillator.
    Geelen P; Lorga Filho A; Chauvin M; Wellens F; Brugada P
    Pacing Clin Electrophysiol; 1997 Jan; 20(1 Pt 2):177-81. PubMed ID: 9121985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Very late effects of dual chamber pacing therapy for obstructive hypertrophic cardiomyopathy.
    Lucon A; Palud L; Pavin D; Donal E; Behar N; Leclercq C; Mabo P; Daubert JC
    Arch Cardiovasc Dis; 2013; 106(6-7):373-81. PubMed ID: 23806305
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gender differences in dual-chamber pacemaker implantation indications and long-term outcomes.
    Dębski M; Ulman M; Ząbek A; Haberka K; Lelakowski J; Małecka B
    Acta Cardiol; 2016 Feb; 71(1):41-5. PubMed ID: 26853252
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complications of permanent cardiac pacing in patients with persistent left superior vena cava.
    Polewczyk A; Kutarski A; Czekajska-Chehab E; Adamczyk P; Boczar K; Polewczyk M; Janion M
    Cardiol J; 2014; 21(2):128-37. PubMed ID: 24526508
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.